Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Melanoma Success Paves Way For Path Of Gold In Cancer Immunotherapy

Executive Summary

Phase I data for immune checkpoint molecules in melanoma from Bristol, Roche and Merck were a major highlight of the ASCO 2013 annual meeting. Considering potential application in many cancers regardless of genetic mutations, some analysts are predicting billions in future sales.

You may also be interested in...



Champagne Flows As CTLA-4/PD-1 Pioneers Allison And Honjo Win Nobel Prize

Joint prize for MD Anderson's James Allison and Kyoto University's Tasuku Honjo for checkpoint immunotherapy reflects decades of research and billions of IO dollars for industry.

Champagne Flows As CTLA-4/PD-1 Pioneers Allison And Honjo Win Nobel Prize

Joint prize for MD Anderson's James Allison and Kyoto University's Tasuku Honjo for checkpoint immunotherapy reflects decades of research and billions of IO dollars for industry.

ASCO 2018: Optimism As Industry Resets And Looks To What Is Next

Investors weren't wildy impressed by the data at ASCO this year, but for pharma, the meeting felt like a renewal, a recommitment to getting it right. It was more a year of refinement as industry digests the advances that have been made, the big mistakes, and pivots toward where to go next. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS055399

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel